Site icon pharmaceutical daily

Duchenne Muscular Dystrophy Drugs Market Poised for Remarkable 39.1% CAGR, Set to Reach $27.4 Billion by 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Duchenne Muscular Dystrophy Drugs – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.


The global market for Duchenne Muscular Dystrophy Drugs, valued at US$2 billion in 2022, is projected to grow to US$27.4 billion by 2030, with a remarkable compound annual growth rate (CAGR) of 39.1% during the analysis period of 2022-2030.

Among the segments analyzed in the report, Exon Skipping is expected to lead the growth with a CAGR of 44.9%, reaching US$18.1 billion by the end of the forecast period. The Steroid Therapy segment is estimated to grow at a CAGR of 27.7% over the next 8 years.

Key Market Insights:

Select Competitors:

Key players in the Duchenne Muscular Dystrophy Drugs market include:

Key Attributes:

Report Attribute Details
No. of Pages 220
Forecast Period 2022 – 2030
Estimated Market Value (USD) in 2022 $2 Billion
Forecasted Market Value (USD) by 2030 $27.4 Billion
Compound Annual Growth Rate 38.7%
Regions Covered Global

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/5u5apo

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version